Daiichi Sankyo Co. Ltd.

04/03/2024 | Press release | Distributed by Public on 04/03/2024 06:16

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer(193.7KB